References
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020.
2. Liu Y, Lee JM, Lee C. The challenges and opportunities of a global health crisis: the management and business implications of COVID-19 from an Asian perspective. Asian Business & Management. 2020;19:277-97.
3. Huang AT, Garcia-Carreras B, Hitchings MD, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. MedRxiv. 2020.
4. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes research and clinical practice. 2020;162.
5. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. Journal of Clinical Virology. 2020;127:104354.
6. Malavazos AE, Corsi Romanelli MM, Bandera F, Iacobellis G. Targeting the adipose tissue in COVID‐19. Obesity. 2020;28(7):1178-9.
7. Wang F, Qu M, Zhou X, Zhao K, Lai C, Tang Q, et al. The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China. Journal of Translational Medicine. 2020;18(1):1-11.
8. Halvatsiotis P, Kotanidou A, Tzannis K, Jahaj E, Magira E, Theodorakopoulou M, et al. Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. Diabetes research and clinical practice. 2020;166:108331.
9. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawaf M. Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in UK: A retrospective single centre study. Diabetes Research and Clinical Practice. 2020.
10. Zhang J, Kong W, Xia P, Xu Y, Li L, Li Q, et al. Impaired fasting glucose and diabetes are related to higher risks of complications and mortality among patients with coronavirus disease 2019. Frontiers in endocrinology. 2020;11:525.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.
12. de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetology & metabolic syndrome. 2020;12(1):1-12.
13. Wells GA, Shea B, O’Connell Da, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
14. Azharuddin M, Adil M, Sharma M, Gyawali B. A systematic review and meta-analysis of non-adherence to anti-diabetic medication: Evidence from low‐and middle‐income countries. Authorea Preprints. 2021.
15. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology. 2020:1-20.
16. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The lancet Diabetes & endocrinology. 2020;8(10):823-33.
17. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia–a systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):395-403.
18. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. bmj. 2020;368.
19. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. The lancet Diabetes & endocrinology. 2020.
20. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN comprehensive clinical medicine. 2020:1-8.
21. Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J, et al. Clinical Features and Risk Factors of ICU Admission for COVID-19 Patients with Diabetes. Journal of diabetes research. 2020;2020.
22. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43.
23. Ata F, Almasri H, Sajid J, Yousaf Z. COVID-19 presenting with diarrhoea and hyponatraemia. BMJ Case Reports CP. 2020;13(6):e235456.
24. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet Infectious Diseases. 2020;20(6):689-96.
25. Belkhadir J. COVID-19 and diabetes from IDF MENA region. diabetes research and clinical practice. 2020;166:108277.
26. Li G, Deng Q, Feng J, Li F, Xiong N, He Q. Clinical characteristics of diabetic patients with COVID-19. Journal of diabetes research. 2020;2020.
27. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes research and clinical practice. 2020;166:108347.
28. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes research and clinical practice. 2020;164:108214.
29. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. 2020;8(5):475-81.